Arancha Rodríguez Caballero

Arancha Rodríguez Caballero

Auto-generated profile, based on publicly available information

Arancha Rodríguez Caballero

Translational and Clinical Research Program, Cancer Research Center Institute of Cancer Molecular and Cellular Biology (IBMCC), University of Salamanca-The Spanish National Research Council (USAL-CSIC), Department of Medicine and Cytometry Service, Nucleus Research Support Platform from University of Salamanca (NUCLEUS), University of Salamanca, Salamanca, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2013 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
MTMaría Dolores Tabernero
María Dolores Tabernero
MJMaría Jara-Acevedo
María Jara-Acevedo
ANAna Belén Nieto-Librero
Ana Belén Nieto-Librero
ACArancha Rodríguez Caballero
Arancha Rodríguez Caballero
AOAlvaro Otero-Rodríguez
Alvaro Otero-Rodríguez
AOAlberto Orfao
Alberto Orfao
Meningioma was the first solid tumor shown to contain a recurrent genetic alteration e.g. monosomy 22/del(22q), NF2 being the most relevant gene involved. Although monosomy 22/del(22q) is present in half of all meningiomas, and meningiomas frequently carry NF2 mutations, no study has been reported so far in which both alterations are simultaneously assessed and correlated with the features of the disease.

26 October 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
ARArancha Rodríguez-Caballero
Arancha Rodríguez-Caballero
BHBlanca Fuentes Herrero
Blanca Fuentes Herrero
GAGuillermo Oliva Ariza
Guillermo Oliva Ariza
ICIgnacio Criado
Ignacio Criado
MAMiguel Alcoceba
Miguel Alcoceba
AOAlberto Orfao
Alberto Orfao
The HCDR3 sequences of the B-cell receptor (BCR) undergo constraints in length, amino acid use, and charge during maturation of B-cell precursors and after antigen encounter, leading to BCR and antibodies with high affinity to specific antigens. Chronic lymphocytic leukemia consists of an expansion of B-cells with a mixed immature and “antigen-experienced” phenotype, with either a mutated (M-CLL) or unmutated (U-CLL) tumor BCR, associated with distinct patient outcomes. Here, we investigated the hydropathy index of the BCR of 138 CLL patients and its association with the IGHV mutational status and patient outcome. Overall, two clearly distinct subgroups of M-CLL patients emerged, based on a neutral (mean hydropathy index of -0.1) vs. negatively charged BCR (mean hydropathy index of -1.1) with molecular features closer to those of B-cell precursors and peripheral/mature B-cells, respectively. Despite that M-CLL with neutral HCDR3 did not show traits associated with a mature B-cell repertoire, important differences in IGHV gene usage of tumor cells and patient outcome were observed in this subgroup of patients once compared to both U-CLL and M-CLL with negatively charged HCDR3 sequences. Compared to M-CLL with negatively charged HCDR3 sequences, M-CLL with neutral HCDR3 sequences showed predominance of men, more advanced stages of the disease, and a greater frequency of genetic alterations—e.g., del(17p)—together with a higher rate of disease progression and shorter time to therapy (TTT), independently of other prognostic factors. Our data suggest that the hydropathy index of the HCDR3 sequences of CLL cells allows the identification of a subgroup of M-CLL with intermediate prognostic features between U-CLL and the more favorable subgroup of M-CLL with a negatively charged BCR.